Characterization of the human folate receptor alpha via novel antibody-based probes

Oncotarget

Volumn 2, Issue 12, 2011, Pages 1227-1243

  O'Shannessy, Daniel J ^a   Somers, Elizabeth B ^a   Albone, Earl ^a   Cheng, Xin ^a   Park, Young Chul ^a   Tomkowicz, Brian E ^b   Hamuro, Yoshitomo ^c   Kohl, Thomas O ^d   Forsyth, Tracy M ^d   Smale, Robert ^e   Fu, Yao Shi ^e   Nicolaides, Nicholas C ^a  

^a Morphotek Inc   (United States)

^b CENTOCOR INC   (United States)

^c ExSAR Corporation   (United States)

^d Rockland Immunochemical Inc   (United States)

^e LABORATORY CORPORATION OF AMERICA   (United States)

Author keywords

26B3; Cancer; Diagnostics; Folate receptor alpha; Monoclonal antibody; Protein structure

Indexed keywords

FOLATE RECEPTOR 1; MONOCLONAL ANTIBODY; RECEPTOR ANTIBODY; CELL SURFACE RECEPTOR; EPITOPE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; FEMALE; MOLECULAR PROBE; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN STRUCTURE; STRUCTURE ANALYSIS; BIOSYNTHESIS; CELL LINE; CELL MEMBRANE; CELL STRAIN HEK293; DEUTERIUM HYDROGEN EXCHANGE; EPITOPE MAPPING; GENETICS; HUMAN; IMMUNOLOGY; METHODOLOGY; ULTRASTRUCTURE;

ANTIBODIES, MONOCLONAL; CELL LINE; CELL MEMBRANE; DEUTERIUM EXCHANGE MEASUREMENT; EPITOPE MAPPING; EPITOPES; FOLATE RECEPTOR 1; HEK293 CELLS; HUMANS; RECEPTORS, CELL SURFACE;

EID: 84862977144     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.412     Document Type: Article

References (39)

1. Choi SW, Mason JB. Folate and carcinogenesis: an integrated scheme. J Nutr. 2000; 130: 129-32.
2. Matherly LH, Goldman DI. Membrane transport of folates. Vitam Horm. 2003; 66: 403-56.
3. Elnakat H, Ratnam M. Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv Drug Deliv Rev. 2004; 56: 1067-84.
4. Basal E, Eghbali-Fatourechi GZ, Kalli KR, Hartmann LC, Goodman KM, Goode EL, Kamen BA, Low PS, Knutson KL. Functional folate receptor alpha is elevated in the blood of ovarian cancer patients. PLoS One. 2009; 4: e6292.
5. Reddy JA, Haneline LS, Srour EF, Antony AC, Clapp DW, Low PS. Expression and functional characterization of the beta-isoform of the folate receptor on CD34(+) cells. Blood. 1999; 93: 3940-48.
6. Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, Leamon C. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem. 2005; 338: 284-93.
7. Garin-Chesa P, Campbell I, Saigo PE, Lewis JL, Old LJ, Rettig WJ. Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. Am J Pathol. 1993; 142: 557-67.
8. Keleman LE. The role of folate receptor a in cancer development, progression and treatment: Cause, consequence or innocent bystander? Int J Cancer. 2006; 119: 243-50.
9. Shia J, Klimstra DS, Nitzkorski JR, Low PS, Gonen M, Landmann R, Weiser MR, Franklin WA, Prendergast FG, Murphy L, Tang LH, Temple L, Guillem JG, Wong WD, Paty PB. Immunohistochemical expression of folate receptor alpha in colorectal carcinoma: patterns and biological significance. Hum Pathol. 2008; 39: 498-505.
10. Franklin WA, Waintrub M, Edwards D, Christensen K, Prendegrast P, Woods J, Bunn PA, Kolhouse JF. New anti-lung-cancer antibody cluster 12 reacts with human folate receptors present on adenocarcinoma. Int J Cancer Suppl. 1994; 8: 89-95.
11. Stein R, Goldenberg DM, Matter MJ. Normal tissue reactivity of four anti-tumor monoclonal antibodies of clinical interest. Int J Cancer. 1991; 47: 163-69.
12. Toffoli G, Cernigoi C, Russo A, Gallo A, Bagnoli M, Boicchi M. Overexpression of folate binding protein in ovarian cancers. Int J Cancer. 1997; 74: 193-98.
13. Toffoli G, Russo A, Gallo A, Cernigoi C, Miotti S, Sorio R, Tumolo S, Boicchi M. Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer. Int J Cancer. 1998; 79: 121-26.
14. Bottero F, Tomassetti A, Canevari S, Miotti S, Menard S, Colnaghi MI. Gene transfection and expression of the ovarian carcinoma marker folate binding protein on NIH/3T3 cells increases cell growth in vitro and in vivo. Cancer Res. 1993; 53: 5791-96.
15. Figini M, Ferri R, Mezzanzanica D, Bagnoli M, Luison E, Miotti S Canevari S. Reversion of transformed phenotype in ovarian cancer cells by intracellular expression of anti folate receptor antibodies. Gene Therapy. 2003; 10: 1018- 25.
16. Jhaveri MS, Rait AS, Chung KN, Trepel JB, Chang EH. Antisense oligonucleotides targeted to the human alpha folate receptor inhibit breast cancer cell growth and sensitize the cells to doxorubicin treatment. Mol Cancer Ther. 2004; 12: 1505-12.
17. Ebel W, Routhier E, Foley B, Jacob S, McDonough J, Patel R, Turchin H, Chao Q, Old LJ, Phillips M., Nicolaides NC, Sass PM, Grasso L. Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun. 2007; 7: 6-14.
18. Miotti S, Bagnoli M, Tomasetti A, Colnagi MI, Canevari S. Interaction of folate receptor with signaling molecules lyn and G(alpha)(i-3) in detergent-resistant complexes from the ovary carcinoma cell line IGROV1. J Cell Sci. 2000; 113: 349-57.
19. Jackman AL, Theti DS, Gibbs DD. Antifolates targeted specifically to the folate receptor. Adv Drug Delivery Rev. 2004; 56: 1111-25.
20. Konner JA, Bell-McGuinn KM, Sabbatini P, Hensley ML, Tew WP, Pandit-Tasker N, Vander Els N, Phillips MA, Schweizer C, Weil SC, Larsons SM, Old LJ. Farletuzumab, a humanized monoclonal antibody against folate receptor α, in epithelial ovarian cancer: a phase I study. Clin Cancer Res. 2010; 16: 5288-95.
21. Reddy JA, Dorton R, Westrick E, Dawson A, Smith T, Xu LC, Vetzel M, Kleindl P, Vlahov IR, Leamon CP. Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate. Cancer Res. 2007; 67: 4434-42.
22. Whiteman KR, Johnson HA, Xu S, Carrigan CN, Ab O, Pinkas J. Preclinical evaluation of IMGN853, an anti- FOLR1 antibody-maytansinoid conjugate, as a potential therapeutic for ovarian cancer. Am Assoc Cancer Res. 2011.
23. Markert S, Lassman S, Gabriel B, Klar M, Werner M, Gitsch G, Kratz F, Hasenburg A. Alpha-folate receptor expression in epithelial ovarian carcinoma and non-neoplastic ovarian tissue. Anticancer Res. 2008; 28: 3567-72.
24. Kalli KR, Oberg AL, Keeney GL, Christianson TJ, Low PS, Knutson KL, Hartmann LC. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gyn Oncol. 2008; 108: 619-26.
25. Maziarz KM, Monaco HL, Shen F, Ratnam M. Complete mapping of divergent amino acids responsible for differential ligand binding of folate receptors α and β*. J Biol Chem. 1999; 274: 11086-91.
26. Feng Y, Shen J, Streaker ED, Lockwood M, Zhu Z, Low PS, Dimitrov DS. A folate receptor beta-specific monoclonal antibody recognizes activated macrophage of rheumatoid patients and mediates antibody dependent cell-mediated cytotoxicity. Arthritis Res and Therapy. 2011; 13: 1-12.
27. Tripett TM, Garcia S, Manova K, Mody R, Cohen-Gould L, Flintoff W, Bertino JR. Localization of a reduced folate carrier protein in the mitochondria as well as the cell membrane of leukemia cells. Cancer Res. 2001; 61: 1941- 47.
28. Brigle KE, Westin EH, Houghton MT, Goldman ID. Characterization of two cDNAs encoding folate-binding proteins from L1210 murine leukemia cells. Increased expression associated with a genomic rearrangement. J Biol Chem. 1991; 266: 17243-49.
29. Smith AE, Pinkney M, Piggott NH, Calvert H, Milton ID, Lunec J. A novel monoclonal antibody for detection of folate receptor alpha in paraffin-embedded tissues. HYBRIDOMA. 2007; 26: 281-88.
30. Mantovani LT, Miotti S, Ménard S, Canevari S, Raspagliesi F, Bottini C, Bottero F, Colnaghi MI. Folate binding protein distribution in normal tissues and biological fluids from ovarian carcinoma patients as detected by the monoclonal antibodies MOv18 and MOv19. Eur J Cancer. 1994; 30A: 363-69.
31. Abdiche YN, Malashock DS, Pinkerton A, Pons J. Exploring blocking assays using Octet, ProteOn, and Biacore biosensors. Anal Biochem. 2009; 386: 172-80.
32. Coales SJ, Tuske SJ, Tomasso JC, Hamuro Y. Epitope mapping by amide hydrogen/deuterium exchange coupled with proteolysis and liquid chromatography mass spectrometry. Rapid Comm Mass Spectrometry. 2009; 23: 639-47.
33. Bueno R, Appasani K, Mercer H, Lester S, Sugarbaker D. The folate receptor is highly activated in malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2001; 121: 0225- 33.
34. D'Angelica M, Ammori J, Gonen M, Klimstra DS, Low PS, Murphy L, Weiser MR, Paty PB, Fong Y, DeMatteo RP, Allen P, Jarnagin WR, Shia J. Folate receptor-α expression in resectable hepatic colorectal cancer metastases: patterns and significance. Mod Pathology. 2011; 24: 1221-28.
35. Elnakat H, Ratnam M. Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv Drug Deliv Rev. 2004; 56: 1067-84.
36. Shen F, Wang H, Zheng X, Ratnam M. Expression levels of functional folate receptors alpha and beta are related to the number of N-glycosylated sites. Biochem J. 1997; 327: 759-64.
37. Knutson KL, Krco CJ, Erskine CL, Goodman K, Kelemen LE, Wettstein PJ, Low PS, Hartmann LC, Kalli KR. T-Cell Immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer. J Clin Onc. 2006; 26: 4254- 61.
38. Simons K, Toomre D. Lipid rafts and signal transduction. Nature Rev. 2000; 1: 31-40.
39. Tomkowicz B, Rybinski K, Foley B, Ebel W, Kline B, Routhier E, Sass P, Nicolaides NC, Grasso L, Zhou Y. Expression of human endosialin (CD248) promotes cellular adhesion to fibronectin through direct binding and activation of β1 integrins. Proc Natl Acad Sci. 2007; 104: 17965-70.